UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 77

Sortiert nach

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

Cancer Immunology, Immunotherapy, 2020-07, Vol.69 (7), p.1353-1362

2020

Volltextzugriff (PDF)

Novel immunotherapies in the treatment of AML: is there hope?

Hematology, 2023-12, Vol.2023 (1), p.691

2023

Volltextzugriff (PDF)

T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?

Deutsche medizinische Wochenschrift (1946), 2024-05, Vol.149 (11), p.630

2024

Volltextzugriff (PDF)

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Blood, 2022-07, Vol.140 (4), p.349-358

2022

Volltextzugriff (PDF)

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Blood, 2022-11, Vol.140 (Supplement 1), p.3227-3228

2022

Volltextzugriff (PDF)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Blood, 2022-11, Vol.140 (20), p.2175-2179

2022

Volltextzugriff (PDF)

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

Neurology, 2022-05, Vol.98 (21), p.884

2022

Volltextzugriff (PDF)

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study

European journal of cancer (1990), 2024-06, Vol.204, p.114071-114071, Article 114071

2024

Volltextzugriff (PDF)

Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e19500-e19500

2023

Volltextzugriff (PDF)

“My T Cell”: A Smartphone Application for Guidance of CAR T Logistics and Management of CAR T & BiTE Related Toxicities

Blood, 2021-11, Vol.138 (Supplement 1), p.1926-1926

2021

Volltextzugriff (PDF)

Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD200

British journal of haematology, 2017-11, Vol.179 (3), p.480-487

2017

Volltextzugriff (PDF)

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Blood, 2020-11, Vol.136 (Supplement 1), p.24-25

2020

Volltextzugriff (PDF)

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

European journal of nuclear medicine and molecular imaging, 2023-04, Vol.50 (5), p.1406-1413

2023

Volltextzugriff (PDF)

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Blood, 2021-11, Vol.138 (Supplement 1), p.2237-2237

2021

Volltextzugriff (PDF)

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Blood, 2021-11, Vol.138 (Supplement 1), p.1178-1178

2021

Volltextzugriff (PDF)

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia

Leukemia, 2022-09, Vol.36 (9), p.2208-2217

2022

Volltextzugriff (PDF)

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency

Neurology : neuroimmunology & neuroinflammation, 2019-11, Vol.6 (6), p.e628-e628

2019

Volltextzugriff (PDF)

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Leukemia, 2024-02, Vol.38 (2), p.398-402

2024

Volltextzugriff (PDF)

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report

BMC infectious diseases, 2021-01, Vol.21 (1), p.121-8, Article 121

2021

Volltextzugriff (PDF)

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

Molecular cancer therapeutics, 2020-09, Vol.19 (9), p.1875-1888

2020

Volltextzugriff (PDF)

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

American journal of hematology, 2023-11, Vol.98 (11), p.1699-1710

2023

Volltextzugriff (PDF)

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Blood, 2022-11, Vol.140 (Supplement 1), p.7421-7422

2022

Volltextzugriff (PDF)

1 – 25 von 77

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(77)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A comparative view on the expression patterns of PD-L1 and PD-1 in soft tissue sarcomas

Technical Aspects of Flow Cytometry‐based Measurable Residual Disease Quantification in Acute Myeloid Leukemia: Experience of the European LeukemiaNet MRD Working Party

Novel immunotherapies in the treatment of AML: is there hope?

CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

T-cell recruiting immunotherapies in B-cell lymphoma - the future backbone for all therapy lines?

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Oligoclonal T-cell expansion in a patient with bone marrow failure after CD19 CAR-T therapy for Richter-transformed DLBCL

Toxicities and Response Rates of Secondary CNS Lymphoma After Adoptive Immunotherapy With CD19-Directed Chimeric Antigen Receptor T Cells

Application of blinatumomab, a bispecific anti-CD3/CD19 T-cell engager, in treating severe systemic sclerosis: A case study

Influence of modified Lugano criteria by pre-infusion tumor kinetics on early survival prediction for patients with lymphoma under chimeric antigen receptor T-cell therapy

“My T Cell”: A Smartphone Application for Guidance of CAR T Logistics and Management of CAR T & BiTE Related Toxicities

Diagnosis of CLL revisited: increased specificity by a modified five‐marker scoring system including CD200

Treosulfan- Versus Melphalan-Based Reduced Intensity Conditioning in Sequential HLA-Haploidentical Transplantation Using Ptcy As GvHD Prophylaxis in High-Risk MDS /AML of the Elderly: A Matched-Pair Analysis

Prognostic value of the International Metabolic Prognostic Index for lymphoma patients receiving chimeric antigen receptor T-cell therapy

Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse

CD33 BiTE ® Construct Mediated Immunological Synapse Formation and Downstream Signaling in T Cells Is Dependent on Expression of Costimulatory Molecules on Target Cells

Augmenting Efficacy of T-Cell Bispecific Antibodies in AML through a Tumor Stroma-Targeted 4-1BB Agonist

Reproducible measurable residual disease detection by multiparametric flow cytometry in acute myeloid leukemia

Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency

Combining venetoclax and azacytidine with T-cell bispecific antibodies for treatment of acute myeloid leukemia: a preclinical assessment

Severe Candida glabrata pancolitis and fatal Aspergillus fumigatus pulmonary infection in the setting of bone marrow aplasia after CD19-directed CAR T-cell therapy - a case report

Characterization of a Novel FLT3 BiTE Molecule for the Treatment of Acute Myeloid Leukemia

The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

Distinguishing Early Infections from CRS with Routine and Exploratory Serum Proteomics and the HT10 Score Following CD19 CAR-T for Relapsed/Refractory B-NHL

Suchergebnisse filtern